Genetic factors in colorectal cancer
Moving in bioRxiv, Gut, Nature Medicine, The lancet. Gastroenterology & hepatology, Gastroenterology, Cancer Discovery, Cancer Research and eLife.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 26
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Genetic factors in colorectal cancer
Newest first · last 60 days
Adenoma immune profiles, especially CD3+ T cell density, predict future colorectal neoplasia with an odds ratio of 1.44 in a bowel screening cohort.
- Open access
CTHRC1-expressing CAFs are linked to poor outcomes and immune resistance in both pMMR/MSS and dMMR/MSI colorectal cancers.
- Open access
- 2 cites
Cancer cells from five different organs show a fourfold increase in mutational burden compared to normal cells, highlighting a significant difference in mutation accumulation.
Brca1 coiled-coil domain mutants retain the ability to suppress Group 1 tandem duplications in mouse cells and tumor models despite impaired homologous recombination functions.
- Open access
Having 5 to 10 nonadvanced adenomas is linked to a 10.1% 5-year risk of advanced colorectal neoplasm, the highest among studied groups.
AI-assisted colonoscopy did not significantly increase adenoma detection rate in Lynch syndrome surveillance, with a difference of 2.9% (p=0.41) in a multicentre trial.
- Open access
- 1 cites
MSS colorectal cancers evade immune responses through intrinsic secretome-driven mechanisms, despite identical antigen presentation to MSI tumors.
- Open access
RO7589831 demonstrates a manageable safety profile and a 74.2% disease control rate in patients with MSI solid tumors in a phase 1 trial.
- Open access
- 1 cites
Cooperative action of two conserved Glu/Asp residues is essential for early ATP hydrolysis in GHKL ATPases, with mutations impairing activity in human disease variants.
- Open access
Multi-cancer gene panels identify pathogenic variants in 4.8% of individuals not meeting testing criteria, missing 22% of actionable hereditary cancer cases.
- Open access
DNA repair pathway choice between homologous recombination and non-homologous end joining is regulated by DNA end resection and specific repair factors.
Circulating tumor DNA-guided treatment in high-risk stage II and III colon cancer achieved a 2-year relapse-free rate of 88% among ctDNA-negative patients, but did not meet the predefined threshold.
- Open access
Add Genetic factors in colorectal cancer as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6131
- medRxiv1703
- PNAS447
- Sci Adv354
- JAMA262
- Environ Res230
- BMJ182
- Environ Pollution165
- Nat Commun161
- Science141
- Nature138
- Lancet128
- Cell Rep120
- NEJM119
- mBio107
- Plant Cell Environ107
- Curr Biol106
- J Exp Bot106
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3